ES2054740T3 - Pentadienamidas paf-antagonistas. - Google Patents

Pentadienamidas paf-antagonistas.

Info

Publication number
ES2054740T3
ES2054740T3 ES88110934T ES88110934T ES2054740T3 ES 2054740 T3 ES2054740 T3 ES 2054740T3 ES 88110934 T ES88110934 T ES 88110934T ES 88110934 T ES88110934 T ES 88110934T ES 2054740 T3 ES2054740 T3 ES 2054740T3
Authority
ES
Spain
Prior art keywords
diseases
paf
pentadienamides
antagonist
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88110934T
Other languages
English (en)
Inventor
Robert William Guthrie
Richard Wightman Kierstead
Jefferson Wright Tilley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2054740T3 publication Critical patent/ES2054740T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

SE DESCRIBEN COMPUESTOS DE LA FORMULA GENERAL (I) DONDE Y ES OXIGENO O UN ATOMO DE AZUFRE Y LOS DEMAS SUSTITUYENTES TIENEN EL SIGNIFICADO DADO EN LA INVENCION. LOS COMPUESTOS DE FORMULA (I) TIENEN ACCION COMO ANTAGONISTAS PAF Y PUEDEN SER APLICADOS EN ENFERMEDADES QUE SE CARACTERIZAN POR ELEVADO PAF O PARA EL TRATAMIENTO DE ALTERACIONES CIRCULATORIAS, ENFERMEDADES DE LOS PULMONES, ALTERACIONES INMUNOLOGICAS, INFLAMACIONES, ENFERMEDADES DE LA PIEL Y RECHAZOS A TRASPLANTES.
ES88110934T 1987-07-10 1988-07-08 Pentadienamidas paf-antagonistas. Expired - Lifetime ES2054740T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/072,389 US4788206A (en) 1987-07-10 1987-07-10 Pentadieneamides

Publications (1)

Publication Number Publication Date
ES2054740T3 true ES2054740T3 (es) 1994-08-16

Family

ID=22107243

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88110934T Expired - Lifetime ES2054740T3 (es) 1987-07-10 1988-07-08 Pentadienamidas paf-antagonistas.

Country Status (21)

Country Link
US (1) US4788206A (es)
EP (1) EP0299379B1 (es)
JP (1) JPS6431766A (es)
KR (1) KR890001989A (es)
AT (1) ATE88466T1 (es)
AU (1) AU626526B2 (es)
CZ (1) CZ394991A3 (es)
DE (1) DE3880387D1 (es)
DK (1) DK378188A (es)
ES (1) ES2054740T3 (es)
FI (1) FI883290A7 (es)
HU (1) HU205902B (es)
IL (1) IL87017A0 (es)
MC (1) MC1954A1 (es)
MX (1) MX9203599A (es)
NO (1) NO883084L (es)
NZ (1) NZ225327A (es)
PH (1) PH24605A (es)
PT (1) PT87953B (es)
YU (1) YU46716B (es)
ZA (1) ZA884857B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL87019A (en) * 1987-07-10 1993-07-08 Hoffmann La Roche Substituted alkene carboxamides and derivatives, their manufacture and pharmaceutical compositions containing them
US5369106A (en) * 1989-04-28 1994-11-29 Sankyo Company, Limited N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists
US5192766A (en) * 1989-04-28 1993-03-09 Sankyo Company, Limited N-acryloylpiperazine derivatives, their preparation and their use as PAF antagonists
KR100568997B1 (ko) * 1996-04-23 2006-12-15 타가셉트 인코포레이티드 중추신경계질환의예방및치료를위한약제학적조성물
JP4357001B2 (ja) * 1996-04-23 2009-11-04 ターガセプト，インコーポレイテッド 中枢神経系障害の予防及び治療のための医薬組成物
AU2652397A (en) * 1996-05-13 1997-12-05 Nippon Shinyaku Co. Ltd. Substituted ethylene compounds and drugs
AU2160899A (en) * 1997-12-11 1999-06-28 Janssen Pharmaceutica N.V. Retinoic acid mimetic anilides
US6232316B1 (en) 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
DE19828463A1 (de) * 1998-06-26 1999-12-30 Basf Ag 4,4-Diarylbutadiene als wasserlösliche photostabile UV-Filter für kosmetische und pharmazeutische Zubereitungen
JP2003501416A (ja) * 1999-06-07 2003-01-14 ターガセプト，インコーポレイテッド 医薬組成物およびその使用法
US6455554B1 (en) 1999-06-07 2002-09-24 Targacept, Inc. Oxopyridinyl pharmaceutical compositions and methods for use
ATE420644T1 (de) * 2002-02-20 2009-01-15 Abbott Lab Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1)
WO2004078144A2 (en) * 2003-03-05 2004-09-16 Celgene Corporation Diphenylethylene compounds and uses thereof
US7781478B2 (en) * 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1771169A1 (en) * 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
US7772271B2 (en) * 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) * 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008507518A (ja) * 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するためのチエノピリジン
EP2050734A1 (en) 2006-07-13 2009-04-22 Kyowa Hakko Kirin Co., Ltd. Pentadienamide derivative
TW200824687A (en) 2006-08-25 2008-06-16 Abbott Lab Compounds that inhibit TRPV1 and uses thereof
KR101660059B1 (ko) * 2008-08-22 2016-09-26 박스알타 인코퍼레이티드 중합체 벤질 카르보네이트-유도체

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3072649A (en) * 1963-01-08 S-tmalkoxycinnamamide derivatives
US4568687A (en) * 1983-02-28 1986-02-04 American Cyanamid Company N-[2-4-(1H-Imidazol-1-yl)alkyl]-arylamides and pharmaceutical compositions
US4568685A (en) * 1984-02-29 1986-02-04 American Cyanamid Company N-[(1H-1,2,4-Triazol-1-yl)alkyl]-arylamides
US4542145A (en) * 1984-02-29 1985-09-17 American Cyanamid Company Substituted N-[(1H-1,2,4-triazol-1-yl)-alkyl]heteroarylcarboxamides
US4673684A (en) * 1984-04-04 1987-06-16 Terumo Corporation Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient
JPS6144870A (ja) * 1984-08-10 1986-03-04 Terumo Corp 不飽和脂肪酸アミド誘導体およびこれを含有する血小板凝集抑制剤
JPS6144869A (ja) * 1984-08-10 1986-03-04 Terumo Corp イミダゾ−ル誘導体およびこれを含有する血小板凝集抑制剤
JPS6212757A (ja) * 1985-07-10 1987-01-21 Yoshitomi Pharmaceut Ind Ltd 桂皮酸アミド誘導体
US4778796A (en) * 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
JPH06144869A (ja) * 1992-11-10 1994-05-24 Matsunami Glass Kogyo Kk バイオ担体用多孔質ガラス

Also Published As

Publication number Publication date
ZA884857B (en) 1989-04-26
FI883290A0 (fi) 1988-07-08
ATE88466T1 (de) 1993-05-15
YU46716B (sh) 1994-04-05
DE3880387D1 (de) 1993-05-27
PH24605A (en) 1990-08-17
IL87017A0 (en) 1988-12-30
YU132488A (en) 1991-02-28
EP0299379A1 (de) 1989-01-18
AU1885188A (en) 1989-01-12
US4788206A (en) 1988-11-29
DK378188A (da) 1989-01-11
DK378188D0 (da) 1988-07-07
FI883290A7 (fi) 1989-01-11
PT87953B (pt) 1995-03-01
MC1954A1 (fr) 1989-06-30
NO883084D0 (no) 1988-07-08
HU205902B (en) 1992-07-28
KR890001989A (ko) 1989-04-07
NO883084L (no) 1989-01-11
CZ394991A3 (en) 1993-01-13
JPS6431766A (en) 1989-02-02
MX9203599A (es) 1992-07-01
EP0299379B1 (de) 1993-04-21
HUT48594A (en) 1989-06-28
PT87953A (pt) 1989-06-30
AU626526B2 (en) 1992-08-06
NZ225327A (en) 1991-08-27

Similar Documents

Publication Publication Date Title
ES2054740T3 (es) Pentadienamidas paf-antagonistas.
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
DE69106586D1 (de) Verwendung von Baclofen zur Herstellung von Arzneimitteln zur Behandlung von Angina pectoris.
GR79463B (es)
ES2032456T3 (es) Procedimiento para preparar derivados de 1,2,5,6-tetrahidropiridin-3-carboxaldehido-oxima.
ES2061559T3 (es) Triazolinonas substituidas.
ATE16489T1 (de) Aroylimidazolone.
ES2134777T3 (es) Nuevos compuestos de sulfonilo.
ES2063397T3 (es) Elaboracion de cauchos de poliuretano.
ES2045009T3 (es) El acido taurohyodesoxicolico para la terapia de calculosis del tracto biliar y de la dispepsia biliar.
ES2060239T3 (es) Analogos de bis(alquil-sustituido-4-hidroxifeniltio)alcano como inhibidores de la formacion de cataratas.
ATE9437T1 (de) Pharmazeutisches mittel zur heilung von entzuendlichen und/oder degenerativen und/oder atrophischen schleimhauterkrankungen.
ES2043725T3 (es) Aminofenil-carbamatos substituidos.
ATE124681T1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
ATE71078T1 (de) Glyzerinderivate.
JPS51116092A (en) Footwear for automatically treating defecation of seriously limbs handicapped patient or the like
ES2059444T3 (es) Procedimiento para la obtencion de acroleinas alfa,beta-substituidas.
MX6274E (es) Procedimiento para la preparacion de composiciones parmaceuticas que contienen alcohilantes citostaticos destoxificados
ES2052622T3 (es) Derivados de benzodioxol, compuestos que los comprenden y utilizacion de los mismos para la fabricacion de medicamentos.
JPS57185270A (en) Novel cyclic sulfenamides, manufacture and use as drug
DK277387D0 (da) Terapeutisk topikal sammensaetning mod en hyperprolifererende epithelsygdom
ES2051778T3 (es) Procedimiento para preparar nuevas imidazo- y triazolotiadiazinas.
ES2053621T3 (es) Un procedimiento para preparar ciertas oxazolonas triciclicas cardiotonicas.
JPS56154456A (en) S-alkyl-3-alkylthiopropionothioates, nanufacture and medicine
SE8502285D0 (sv) Antibakteriell komposition

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 299379

Country of ref document: ES